Initial Empiric Therapy for Fever in Neutropenia

  • C. I. Bustamante
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 132)

Abstract

Despite significant improvements in supportive care, infection remains a significant cause of morbidity and mortality for patients with cancer undergoing intensive chemotherapy. This is particularly important for patients with hematologic malignancies receiving induction-chemotherapy or bone marrow transplantation. Neutropenia (<1000 granulocytes/μl) is the most significant risk factor with the majority of the infections developing at a granulocyte count <500/μl and almost all the bacteremias at <100 granulocytes/μl (Bodey et al. 1966).

Keywords

Oncol Beach Glycoside Gentamicin Cytosine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baglin TP, Gray JJ, Marcus RE, Wreghitt TG (1989) Antibiotic resistant fever associated with herpes simplex virus infection in neutropenic patients with haematological malignancy. J Clin Pathol 42: 1255–1258PubMedCrossRefGoogle Scholar
  2. Bodey GP, Buckley M, Sathe YS et al. (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328–340PubMedGoogle Scholar
  3. Bustamante CI, Wharton RC, Moody MA, Novak M, Talley E, Saba G, Wade JC (1986) Imipenem induced concentration dependent antagonism when combined with β-lactams. American Society of Microbiology, Washington, D.C., abstract #A95Google Scholar
  4. Bustamante CI, Drusano GL, Wharton RC, Wade JC (1987) Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob Agents Chemother 31: 632–634PubMedGoogle Scholar
  5. Bustamante CI, Wharton RC, Wade JC (1990) In vitro activity of ciprofloxacin with ceftazidime, aztreonam and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 34: 1814–1815PubMedGoogle Scholar
  6. de Jongh CA, Joshi JH, Newman KA, Moody MR, Wharton R, Standiford HC, Schimpff SC (1986) Antibiotic synergism and response in Gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 80: 96–100PubMedCrossRefGoogle Scholar
  7. EORTC International Antimicrobial Therapy Cooperative Group (1987) Ceftazidime combined with a short or long course of amikacin for empiric therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317: 1692–1698CrossRefGoogle Scholar
  8. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, Yow MD (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161: 381–396PubMedCrossRefGoogle Scholar
  9. Karp JE, Dick JD, Angelopulos C et al. (1986) Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Am J Med 81: 237–242PubMedCrossRefGoogle Scholar
  10. Klastersky J, Meunier-Carpentier F, Prevost J-M (1977) Significance of antimicrobial synergism for the outcome of Gram-negative sepsis. Am J Med Sci 273: 157–167PubMedCrossRefGoogle Scholar
  11. Klastersky J, Zinner SH, Calandra T et al. (1988) Empiric antimicrobial therapy for febrile granulocytopenic patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 24 [Suppl]: S35–S45PubMedCrossRefGoogle Scholar
  12. Love LJ, Schimpff SC, Schiffer, CA, Wiernik PH (1980) Improved prognosis for granulocytopenic patients with Gram-negative bacteremia. Am J Med 68: 643–648PubMedCrossRefGoogle Scholar
  13. Pizzo PA, Hathorn JW, Hiemenz J et al. (1986) A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315: 552–558PubMedCrossRefGoogle Scholar
  14. Pizzo PA, Armstrong D, Bodey G et al. (1990) The design, analysis and reporting of clinical trials on the empiric antibiotic management of the neutropenic patient. J Infect Dis 161: 397–401CrossRefGoogle Scholar
  15. Rubin M, Hathorn JW, Marshall D et al. (1988) Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Inter Med 108: 30–35Google Scholar
  16. Schiffer CA, Wade JC (1987) Supportive care: issues in the use of blood products and treatment of infection. Semin Oncol 14: 454–467PubMedGoogle Scholar
  17. Schimpff SC (1990) Infections in the compromised host - an overview. In: Mandell GL, Douglas RG JR, Bennett JE (eds) Principles and practice of infectious diseases, 3rd edn. Churchill Livingstone, New York, pp 2258–2265Google Scholar
  18. Shenep JL, Hughes WT, Roberson PK, Blankenship KR, Baker DK Jr, Meyer WH, Gigliotti F, Sixbey JW, Santana VM, Feldman S et al. (1988) Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 319: 1053–1058PubMedCrossRefGoogle Scholar
  19. Wade JC, Standiford HC, Drusano GL, Johnson DE, Moody MR, Bustamante CI, Joshi JH, de Jongh CA, Schimpff SC (1985) Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. Am J Med 78: 62–72Google Scholar
  20. Wade JC, Johnson DE, Bustamante CI (1986) Monotherapy for empiric treatment for fever in granulocytopenic cancer patients. Am J Med 80 [Suppl 5C]: 85–95PubMedGoogle Scholar
  21. Wade JC, Bustamante CI, Devlin A, Finley R, Drusano G, Thompson B (1987) Imipenem versus piperacillin plus amikacin as empiric therapy for febrile neutropenic patients: a double blind trial. Proceedings of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington (abstr) 1251Google Scholar

Further Reading

  1. rHughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, Yow MD (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161:381–396 A concerted effort by leading members of the Infectious Diseases Society of America to design guidelines for the use of antimicrobial agents in neutropenic patients with fever.CrossRefGoogle Scholar
  2. Pizzo PA, Armstrong D, Bodey G et al. (1990) The design, analysis and reporting of clinical trials on the empiric antibiotic management of the neutropenic patient. J Infect Dis 161:397–401 The results of a consensus panel of the Immunocompromised Host Society to facilitate the implementation of uniform designs and analysis of empiric antibiotic trials in neutropenic cancer patients worldwide.CrossRefGoogle Scholar
  3. Schiffer CA, Wade JC (1987) Supportive care: issues in the use of blood products and treatment of infection. Semin Oncol 14:454–467 Comprehensive review on the supportive care of the neutropenic cancer patient with emphasis on the management of empiric antibiotic therapy.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1993

Authors and Affiliations

  • C. I. Bustamante
    • 1
  1. 1.Private Practice of Infectious DiseasesN. Miami BeachUSA

Personalised recommendations